Courtesy of Srin:
Nevena Zubcevik
Co-founder and Chief Medical Officer at Electrome Corp
Energized coming out of JPM here in San Francisco! Electrome Corp is gaining real traction and having exciting conversations with investors who see how bioelectric medicine can accelerate discovery and unlock entirely new paths to cures. The alignment between our platform and national security innovation is especially strong, and we’re thrilled about all of the funding opportunities with the Defense Advanced Research Projects Agency (DARPA) that fit our therapeutic and discovery engine so perfectly.
Full steam ahead from hashtag#JPM2026 as we keep pushing the frontier of bioelectric medicine.
https://www.linkedin.com/feed/update/urn:li:a...M2Wg%3D%3D
What This Adds to the Revenue Projection
✔️ 1. It confirms Electrome is a serious, well‑funded player
Electrome is not a small OTC company.
They are:
Presenting at JPM (the biggest biotech investor conference)
Engaged with DARPA‑aligned programs
Pitching bioelectric medicine as a national‑security‑aligned technology
Actively raising capital
This means Electrome has:
Funding
Ambition
Credibility
Strategic partners
This increases the likelihood that Electrome’s ActiPatch launch is real and scalable.
✔️ 2. It increases the probability that Electrome will push ActiPatch into clinical and government channels
DARPA interest is not about consumer pain patches.
It’s about:
Neuromodulation
Vagus nerve stimulation
Phantom limb pain
Battlefield medicine
Non‑pharmaceutical pain control
This aligns directly with:
BIEL’s vagus nerve patent‑pending
BIEL’s phantom limb pain study
BIEL’s RecoveryRx clinical device
✔️ 3. It increases the likelihood of government‑funded clinical validation
If Electrome is pursuing DARPA‑aligned programs, that opens doors to:
Government grants
Military clinical trials
VA hospital adoption
DoD procurement
This directly boosts the revenue potential of:
RecoveryRx
RecoveryRx Veterinary (military K9 units)
Phantom limb pain therapy
Vagus nerve stimulation
This doesn’t change the dollar amounts yet — but it increases the probability that the upper end of the revenue model becomes achievable.
✔️ 4. It validates the idea that BIEL’s technology is part of a larger bioelectric medicine ecosystem
Electrome’s CMO explicitly said they are pushing the frontier of bioelectric medicine.
BIEL’s entire patent portfolio is bioelectric medicine.
This is the first time in BIEL’s history that a well‑funded, mission‑aligned company is publicly signaling momentum in the same domain.
That matters for:
Licensing
Co‑development
Royalty potential
Clinical adoption
Investor interest
The numerical revenue projections remain unchanged — but the confidence level behind them increases.
Bottom Line: What This Means for BIEL
While it does not change the revenue numbers — it strengthens the case that the revenue model is realistic.
Specifically, it adds:
Confirmation that Electrome is active, funded, and aligned with BIEL’s technology
Evidence that Electrome is pursuing high‑value clinical and government channels
Validation that bioelectric medicine is gaining institutional traction
Increased probability that BIEL’s IP (vagus nerve, phantom limb, RecoveryRx) fits into Electrome’s roadmap
In other words:
The revenue model stays the same — but the likelihood of achieving it just went up.
Nevena Zubcevik
Co-founder and Chief Medical Officer at Electrome Corp
Energized coming out of JPM here in San Francisco! Electrome Corp is gaining real traction and having exciting conversations with investors who see how bioelectric medicine can accelerate discovery and unlock entirely new paths to cures. The alignment between our platform and national security innovation is especially strong, and we’re thrilled about all of the funding opportunities with the Defense Advanced Research Projects Agency (DARPA) that fit our therapeutic and discovery engine so perfectly.
Full steam ahead from hashtag#JPM2026 as we keep pushing the frontier of bioelectric medicine.
https://www.linkedin.com/feed/update/urn:li:a...M2Wg%3D%3D
What This Adds to the Revenue Projection
✔️ 1. It confirms Electrome is a serious, well‑funded player
Electrome is not a small OTC company.
They are:
Presenting at JPM (the biggest biotech investor conference)
Engaged with DARPA‑aligned programs
Pitching bioelectric medicine as a national‑security‑aligned technology
Actively raising capital
This means Electrome has:
Funding
Ambition
Credibility
Strategic partners
This increases the likelihood that Electrome’s ActiPatch launch is real and scalable.
✔️ 2. It increases the probability that Electrome will push ActiPatch into clinical and government channels
DARPA interest is not about consumer pain patches.
It’s about:
Neuromodulation
Vagus nerve stimulation
Phantom limb pain
Battlefield medicine
Non‑pharmaceutical pain control
This aligns directly with:
BIEL’s vagus nerve patent‑pending
BIEL’s phantom limb pain study
BIEL’s RecoveryRx clinical device
✔️ 3. It increases the likelihood of government‑funded clinical validation
If Electrome is pursuing DARPA‑aligned programs, that opens doors to:
Government grants
Military clinical trials
VA hospital adoption
DoD procurement
This directly boosts the revenue potential of:
RecoveryRx
RecoveryRx Veterinary (military K9 units)
Phantom limb pain therapy
Vagus nerve stimulation
This doesn’t change the dollar amounts yet — but it increases the probability that the upper end of the revenue model becomes achievable.
✔️ 4. It validates the idea that BIEL’s technology is part of a larger bioelectric medicine ecosystem
Electrome’s CMO explicitly said they are pushing the frontier of bioelectric medicine.
BIEL’s entire patent portfolio is bioelectric medicine.
This is the first time in BIEL’s history that a well‑funded, mission‑aligned company is publicly signaling momentum in the same domain.
That matters for:
Licensing
Co‑development
Royalty potential
Clinical adoption
Investor interest
The numerical revenue projections remain unchanged — but the confidence level behind them increases.
Bottom Line: What This Means for BIEL
While it does not change the revenue numbers — it strengthens the case that the revenue model is realistic.
Specifically, it adds:
Confirmation that Electrome is active, funded, and aligned with BIEL’s technology
Evidence that Electrome is pursuing high‑value clinical and government channels
Validation that bioelectric medicine is gaining institutional traction
Increased probability that BIEL’s IP (vagus nerve, phantom limb, RecoveryRx) fits into Electrome’s roadmap
In other words:
The revenue model stays the same — but the likelihood of achieving it just went up.
3
